Skip to main content
TOPICS
Videos
Provider
Payer
Pharma
Consumer
Investor
RESOURCES
Events
Jobs
Learning Center
Webinars
White Papers
REGIONS
ANZ
ASIA
EMEA
Global Edition
MORE
About
Advertise
Contact
Privacy Policy
ANZ
ASIA
EMEA
Global Edition
diagnostic companies
OrbiMed secures $1.86B for credit and royalty fund V
By
Anthony Vecchione
|
12:40 pm |
August 06, 2025
The company intends to partner with healthcare, biopharmaceutical, medical device and diagnostic companies.